Published in Biol Blood Marrow Transplant on September 18, 2010
Observational Study of Iron Overload in Stem Cell Transplantation | NCT00954720
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation | NCT00658411
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood (2013) 1.71
How I treat late effects in adults after allogeneic stem cell transplantation. Blood (2010) 1.26
Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One (2011) 1.08
Current therapy of myelodysplastic syndromes. Blood Rev (2013) 1.07
National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction. Biol Blood Marrow Transplant (2011) 1.01
Does iron overload really matter in stem cell transplantation? Am J Hematol (2012) 0.99
Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol (2013) 0.96
Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant (2014) 0.91
Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant (2012) 0.89
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. Cochrane Database Syst Rev (2015) 0.81
Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). Curr Hematol Malig Rep (2014) 0.79
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. Cochrane Database Syst Rev (2015) 0.78
High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome. Tumour Biol (2013) 0.78
Serum hepcidin following autologous hematopoietic cell transplantation: an illustration of the interplay of iron status, erythropoiesis and inflammation. Haematologica (2014) 0.77
Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. Biol Blood Marrow Transplant (2015) 0.76
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. J Clin Oncol (2017) 0.75
Immunoassay for human serum hepcidin. Blood (2008) 5.32
Correction of logistic regression relative risk estimates and confidence intervals for systematic within-person measurement error. Stat Med (1989) 5.08
Iron-chelating therapy and the treatment of thalassemia. Blood (1997) 4.99
MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood (2005) 4.79
Regression calibration method for correcting measurement-error bias in nutritional epidemiology. Am J Clin Nutr (1997) 3.68
A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging (2003) 3.11
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood (2007) 2.54
R2* magnetic resonance imaging of the liver in patients with iron overload. Blood (2009) 2.05
Longitudinal analysis of heart and liver iron in thalassemia major. Blood (2008) 1.94
Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood (2009) 1.63
Quantitative study of the variability of hepatic iron concentrations. Clin Chem (1999) 1.37
Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2008) 1.33
Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol (2009) 1.32
Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant (2002) 1.31
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica (2009) 1.28
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant (2008) 1.19
R2 relaxometry with MRI for the quantification of tissue iron overload in beta-thalassemic patients. J Magn Reson Imaging (2006) 1.17
Molecular mechanisms of normal iron homeostasis. Hematology Am Soc Hematol Educ Program (2009) 1.13
The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol (2009) 1.10
BMT: Serum Ferritin as Risk Factor for Veno-occlusive Disease of the Liver. Prospective Cohort Study. Hematology (2000) 1.09
Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant (2009) 1.04
Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2009) 1.03
Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Bone Marrow Transplant (2009) 0.97
Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies. Acta Haematol (2009) 0.92
Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant (2010) 0.90
Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation. Eur J Haematol (2009) 0.86
High-throughput matrix-assisted laser desorption ionization-time-of-flight mass spectrometry method for quantification of hepcidin in human urine. Anal Chem (2010) 0.86
Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics (2002) 30.58
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature (2008) 8.69
Directed proteomic analysis of the human nucleolus. Curr Biol (2002) 7.04
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02
Toward improving Caenorhabditis elegans phenome mapping with an ORFeome-based RNAi library. Genome Res (2004) 5.81
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation (2006) 4.98
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation (2004) 4.58
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood (2006) 4.46
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet (2008) 4.02
Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood (2002) 3.93
Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol (2002) 3.85
Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med (2011) 3.83
Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene (2002) 3.80
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant (2007) 3.58
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood (2002) 3.56
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med (2013) 3.39
Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet (2005) 3.28
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
A mouse model of juvenile hemochromatosis. J Clin Invest (2005) 3.25
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med (2005) 3.19
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 3.08
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet (2003) 3.07
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood (2011) 3.02
Complications of beta-thalassemia major in North America. Blood (2004) 2.97
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood (2004) 2.89
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol (2011) 2.78
Interrelation of coronary calcification, myocardial ischemia, and outcomes in patients with intermediate likelihood of coronary artery disease: a combined positron emission tomography/computed tomography study. Circulation (2008) 2.77
The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation . J Am Coll Cardiol (2013) 2.76
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood (2011) 2.66
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood (2005) 2.65
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood (2007) 2.54
Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell (2002) 2.51
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 2.50
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2006) 2.44
A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg (2011) 2.43
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood (2011) 2.41
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2002) 2.40
The Steap proteins are metalloreductases. Blood (2006) 2.37
Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet (2009) 2.37
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood (2011) 2.33
Cdk5rap2 regulates centrosome function and chromosome segregation in neuronal progenitors. Development (2010) 2.31
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood (2004) 2.30